Published in Hepatitis Weekly, September 22nd, 1997
The randomized, controlled study is expected to take approximately 12 months and will include 240 patients, at approximately 20 facilities nationwide, who receive up to six units of PolyHeme (equivalent to six pints of blood). These advanced trials are the first Phase III study by any company to include direct replacement of blood in large volumes.
"We are pleased to have our first sites ready to begin enrollment," said Richard DeWoskin, Northfield Laboratories,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly